46
Participants
Start Date
April 29, 2013
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2018
Crizotinib
Given PO
Cyclophosphamide
Given IV
Dexrazoxane Hydrochloride
Given IV
Doxorubicin Hydrochloride
Given IV
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Questionnaire Administration
Ancillary studies
Topotecan Hydrochloride
Given IV
Vincristine Sulfate
Given IV
Columbia University/Herbert Irving Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Children's Healthcare of Atlanta - Egleston, Atlanta
Children's Hospital of Alabama, Birmingham
St. Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Wisconsin, Milwaukee
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Children's Hospital of Orange County, Orange
UCSF Medical Center-Parnassus, San Francisco
UCSF Medical Center-Mission Bay, San Francisco
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
Hospital for Sick Children, Toronto
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK